Endocrinologia Diabetes Y Nutricion最新文献

英文中文

In young adult males, bitterness perception is associated with excess body mass and metabolic dysregulation 在年轻成年男性中，苦味感知与超重和代谢失调有关

IF 1.8 4区医学 Q4 ENDOCRINOLOGY & METABOLISM

Endocrinologia Diabetes Y Nutricion

Pub Date : 2025-11-01 Epub Date: 2025-10-29 DOI: 10.1016/j.endien.2025.501629

Julieta Cigarroa-Durán , Gabriel López-Ramírez , Mirian Carolina Martínez-López , Itandehui Castro-Quezada , Arturo Ortega Soto , Orquidia G. Méndez-Flores

Introduction

Bitterness perception requires activation of the taste-receptor cells (TRCs) in the lingual papillae. The TAS2R38 specialist receptor (T2R family) is activated by thiol-urea chemicals, where 3 haplotype combinations are highly related to bitterness perception. Tasters (PAV/PAV) and non-tasters (AVI/AVI) represent the homozygous phenotypes, while the heterozygous combinations form the moderate tasters, who comprise approximately half of the population.

Material and methods

We determined the bitterness perception phenotype of 153 young adults, as they reacted to a phenylthiocarbamide (PTC) impregnated paper strip placed on their tongues. We measured their weight, height, waist and hip circumferences, total body fat and lean body mass. Mean and standard deviation is shown to express quantitative variables, Kruskal–Wallis test and Dunn's multiple comparison test was used, with 95% confidence intervals.

Results

PTC tasters comprised 27% of the study group, with non-tasters making up 18%. When analyzed by sex, 32% of women were PTC tasters vs 18% of men. Notably, for men, PTC tasters exhibited higher mean values across several body composition measures than non-tasters, including a BMI of 28 kg/m² vs 24 kg/m², a waist circumference of 94 cm vs 79 cm, a waist-to-height ratio of 0.54 vs 0.49, and a body fat percentage of 28% vs 15%. In contrast, women showed no significant differences in these measures based on their bitterness perception.

Conclusions

The distribution of perception groups and preponderance of female PTC tasters corresponds to previously reported data. Taster men had a body composition distant from healthy parameters and above the non-tasters values, yet not significant differences were found for female participants.

苦味感知需要激活舌乳头中的味觉受体细胞（TRCs）。TAS2R38特殊受体（T2R家族）被硫醇-尿素化学物质激活，其中3个单倍型组合与苦味感知高度相关。品尝者（PAV/PAV）和非品尝者（AVI/AVI）代表纯合表型，而杂合组合形成中等品尝者，约占人口的一半。材料和方法我们测定了153名年轻人的苦味感知表型，当他们对放在舌头上的浸渍了苯硫脲（PTC）的纸条做出反应时。我们测量了他们的体重、身高、腰围和臀围、全身脂肪和瘦体重。以均数和标准差表示定量变量，采用Kruskal-Wallis检验和Dunn’s多重比较检验，置信区间为95%。结果sptc品酒者占研究组的27%，非品酒者占18%。当按性别分析时，32%的女性是PTC品酒师，而男性是18%。值得注意的是，对于男性来说，PTC品酒师在几项身体成分测量中表现出比非品酒师更高的平均值，包括BMI为28 kg/m2 vs 24 kg/m2，腰围为94 cm vs 79 cm，腰高比为0.54 vs 0.49，体脂率为28% vs 15%。相比之下，女性在这些基于苦味感知的测量中没有显着差异。结论感知组的分布和女性味觉者的优势与先前报道的数据一致。品酒师男性的身体组成远离健康参数，高于非品酒师的值，但女性参与者没有发现显著差异。

{"title":"In young adult males, bitterness perception is associated with excess body mass and metabolic dysregulation","authors":"Julieta Cigarroa-Durán , Gabriel López-Ramírez , Mirian Carolina Martínez-López , Itandehui Castro-Quezada , Arturo Ortega Soto , Orquidia G. Méndez-Flores","doi":"10.1016/j.endien.2025.501629","DOIUrl":"10.1016/j.endien.2025.501629","url":null,"abstract":"<div><h3>Introduction</h3><div>Bitterness perception requires activation of the taste-receptor cells (TRCs) in the lingual papillae. The TAS2R38 specialist receptor (T2R family) is activated by thiol-urea chemicals, where 3 haplotype combinations are highly related to bitterness perception. Tasters (PAV/PAV) and non-tasters (AVI/AVI) represent the homozygous phenotypes, while the heterozygous combinations form the moderate tasters, who comprise approximately half of the population.</div></div><div><h3>Material and methods</h3><div>We determined the bitterness perception phenotype of 153 young adults, as they reacted to a phenylthiocarbamide (PTC) impregnated paper strip placed on their tongues. We measured their weight, height, waist and hip circumferences, total body fat and lean body mass. Mean and standard deviation is shown to express quantitative variables, Kruskal–Wallis test and Dunn's multiple comparison test was used, with 95% confidence intervals.</div></div><div><h3>Results</h3><div>PTC tasters comprised 27% of the study group, with non-tasters making up 18%. When analyzed by sex, 32% of women were PTC tasters vs 18% of men. Notably, for men, PTC tasters exhibited higher mean values across several body composition measures than non-tasters, including a BMI of 28kg/m<sup>2</sup> vs 24kg/m<sup>2</sup>, a waist circumference of 94cm vs 79cm, a waist-to-height ratio of 0.54 vs 0.49, and a body fat percentage of 28% vs 15%. In contrast, women showed no significant differences in these measures based on their bitterness perception.</div></div><div><h3>Conclusions</h3><div>The distribution of perception groups and preponderance of female PTC tasters corresponds to previously reported data. Taster men had a body composition distant from healthy parameters and above the non-tasters values, yet not significant differences were found for female participants.</div></div>","PeriodicalId":48650,"journal":{"name":"Endocrinologia Diabetes Y Nutricion","volume":"72 9","pages":"Article 501629"},"PeriodicalIF":1.8,"publicationDate":"2025-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145374550","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Semaglutide-associated psychiatric disorders: A case report and literature review 塞马格鲁肽相关精神疾病1例报告及文献复习

IF 1.8 4区医学 Q4 ENDOCRINOLOGY & METABOLISM

Endocrinologia Diabetes Y Nutricion

Pub Date : 2025-11-01 Epub Date: 2025-10-29 DOI: 10.1016/j.endien.2025.501613

Alba Escolà-Rodríguez , Berta de Andrés , Tamara Hervis , Marina Rovira-Illamola

引用次数: 0

Coexistance of metastatic papillary thyroid microcarcinoma and medullary thyroid carcinoma in MEN 2B. Case report and literature review MEN 2B中转移性甲状腺乳头状癌和甲状腺髓样癌共存。病例报告及文献复习。

IF 1.8 4区医学 Q4 ENDOCRINOLOGY & METABOLISM

Endocrinologia Diabetes Y Nutricion

Pub Date : 2025-10-01 Epub Date: 2025-09-12 DOI: 10.1016/j.endien.2025.501596

María Díaz-Tobarra , Sara Subirats Bort , Ignacio Peña Saiz de Aja , Gonzalo Villar García , Encarnación Lag Asturiano

引用次数: 0

Therapeutic effects of chromium supplementation on women with polycystic ovarian syndrome: A systematic review and meta-analysis 补充铬对女性多囊卵巢综合征的治疗效果：系统回顾和荟萃分析

IF 1.8 4区医学 Q4 ENDOCRINOLOGY & METABOLISM

Endocrinologia Diabetes Y Nutricion

Pub Date : 2025-10-01 Epub Date: 2025-10-07 DOI: 10.1016/j.endien.2025.501578

Mohammed Hamsho , Yazan Ranneh , Abdulmannan Fadel

Background

Polycystic ovarian syndrome (PCOS) has been treated recently with chromium supplementations. However, it is unknown if this dietary supplement has similar effect to metformin.

Aim

The aim of this study was to investigate the efficacy of chromium supplementation in women with PCOS.

Methods

A meta-analysis was conducted using relevant articles obtained from searches of PubMed, Scopus, Embase, and Google Scholar. The mean difference and standardized mean difference were employed to determine the effect size for biochemical parameters.

Results

A total of 10 randomized controlled trials involving 683 women were included in the analysis. The results indicated that chromium supplementation, as vs a placebo, significantly decreased fasting blood insulin (P = 0.01), triglyceride (P < 0.00001), total cholesterol (P < 0.00001), very low-density lipoprotein (P < 0.00001), low-density lipoprotein (P = 0.0003), high sensitivity C-reactive protein (P = 0.02), malondialdehyde (P = 0.007), follicle stimulating hormone (P = 0.0007), and prolactin (P = 0.01), and increased the Quantitative Insulin Sensitivity Check Index (P = 0.02), total antioxidant capacity (P < 0.0001), and ovulation incidence (P = 0.001). Chromium supplementation was also found to be more effective than metformin in reducing HOMA-IR (P < 0.00001), and luteinizing hormone (P = 0.04).

Conclusion

Chromium picolinate supplementation at a dosage of 200 μg may provide benefits similar to metformin with regard to FBG, FBI, ovulation, and pregnancy incidence, with fewer side effects in patients with PCOS. Further experiments are still required to draw effective dietary guidelines related to chromium.

背景：最近，铬补充剂被用于治疗多囊卵巢综合征（PCOS）。然而，尚不清楚这种膳食补充剂是否具有与二甲双胍相似的效果。目的本研究的目的是探讨铬补充剂对多囊卵巢综合征妇女的疗效。方法采用PubMed、Scopus、Embase和谷歌Scholar检索的相关文章进行meta分析。采用均数差和标准化均数差确定生化参数的效应大小。结果共纳入10项随机对照试验，涉及683名女性。结果表明，与安慰剂相比，添加铬显著降低空腹血胰岛素（P = 0.01）、甘油三酯（P < 0.00001）、总胆固醇（P < 0.00001）、极低密度脂蛋白（P < 0.00001）、低密度脂蛋白（P = 0.0003）、高敏c反应蛋白（P = 0.02）、丙二醛（P = 0.007）、促卵泡激素（P = 0.0007）和催乳素（P = 0.01）。增加了胰岛素敏感性定量检查指数（P = 0.02）、总抗氧化能力（P < 0.0001）和排卵发生率（P = 0.001）。铬补充剂也被发现在降低HOMA-IR （P < 0.00001）和黄体生成素（P = 0.04）方面比二甲双胍更有效。结论补充200 μg吡啶甲酸铬对PCOS患者的FBG、FBI、排卵和妊娠发生率的影响与二甲双胍相似，且副作用更小。还需要进一步的实验来制定与铬有关的有效膳食指南。

{"title":"Therapeutic effects of chromium supplementation on women with polycystic ovarian syndrome: A systematic review and meta-analysis","authors":"Mohammed Hamsho , Yazan Ranneh , Abdulmannan Fadel","doi":"10.1016/j.endien.2025.501578","DOIUrl":"10.1016/j.endien.2025.501578","url":null,"abstract":"<div><h3>Background</h3><div>Polycystic ovarian syndrome (PCOS) has been treated recently with chromium supplementations. However, it is unknown if this dietary supplement has similar effect to metformin.</div></div><div><h3>Aim</h3><div>The aim of this study was to investigate the efficacy of chromium supplementation in women with PCOS.</div></div><div><h3>Methods</h3><div>A meta-analysis was conducted using relevant articles obtained from searches of PubMed, Scopus, Embase, and Google Scholar. The mean difference and standardized mean difference were employed to determine the effect size for biochemical parameters.</div></div><div><h3>Results</h3><div>A total of 10 randomized controlled trials involving 683 women were included in the analysis. The results indicated that chromium supplementation, as vs a placebo, significantly decreased fasting blood insulin (<em>P</em>  <0.00001), total cholesterol (<em>P</em>  <0.00001), low-density lipoprotein (<em>P</em>  =0.02), malondialdehyde (<em>P</em>  =0.0007), and prolactin (<em>P</em>  =0.02), total antioxidant capacity (<em>P</em>  =0.001). Chromium supplementation was also found to be more effective than metformin in reducing HOMA-IR (<em>P</em>  =0.04).</div></div><div><h3>Conclusion</h3><div>Chromium picolinate supplementation at a dosage of 200μg may provide benefits similar to metformin with regard to FBG, FBI, ovulation, and pregnancy incidence, with fewer side effects in patients with PCOS. Further experiments are still required to draw effective dietary guidelines related to chromium.</div></div>","PeriodicalId":48650,"journal":{"name":"Endocrinologia Diabetes Y Nutricion","volume":"72 8","pages":"Article 501578"},"PeriodicalIF":1.8,"publicationDate":"2025-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145236396","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Neuromedin U and BMI correlation in T1DM and T2DM vs healthy controls: A comparative study 1型糖尿病和2型糖尿病患者与健康对照者的神经素U和BMI相关性的比较研究

IF 1.8 4区医学 Q4 ENDOCRINOLOGY & METABOLISM

Endocrinologia Diabetes Y Nutricion

Pub Date : 2025-10-01 Epub Date: 2025-10-07 DOI: 10.1016/j.endien.2025.501631

Yasemin Çalışkan , Emre Sarandöl , Nizameddin Koca

Objective

This study aimed to assess serum Neuromedin U (NmU) levels in patients with Type 1 (T1DM) and Type 2 diabetes mellitus (T2DM) vs healthy controls and evaluate the correlation between NmU and body mass index (BMI).

Research design and methods

We conducted a cross-sectional study with 134 participants: 45 with T1DM, 49 with T2DM, and 40 healthy controls. Serum NmU levels were measured using enzyme-linked immunosorbent assay (ELISA), and the correlation with BMI was assessed.

Results

NmU levels were not significantly different between diabetic patients and healthy controls. No significant correlation was observed between NmU and BMI in T1DM or T2DM groups. However, the healthy control group found a significant inverse correlation between NmU and BMI (rho = −0.373, p < 0.05).

Conclusions

NmU may not be a direct biomarker for diabetes, but its significant correlation with BMI in healthy individuals suggests a potential role in metabolic regulation. This is the first study ever conducted to compare NmU levels across diabetic subtypes, offering novel insights into the role of in metabolic homeostasis.

目的比较1型糖尿病（T1DM）和2型糖尿病（T2DM）患者与健康对照者血清神经medin U （NmU）水平，并评价NmU与体重指数（BMI）的相关性。研究设计和方法我们对134名参与者进行了横断面研究：45名1型糖尿病患者，49名2型糖尿病患者，40名健康对照。采用酶联免疫吸附试验（ELISA）测定血清NmU水平，并评估与BMI的相关性。结果糖尿病患者血清snmu水平与健康对照组无显著差异。T1DM组和T2DM组NmU与BMI无显著相关性。而健康对照组NmU与BMI呈显著负相关（rho = - 0.373, p < 0.05）。结论snmu可能不是糖尿病的直接生物标志物，但其与健康个体BMI的显著相关性提示其在代谢调节中可能发挥作用。这是有史以来第一个比较糖尿病亚型中NmU水平的研究，为其在代谢稳态中的作用提供了新的见解。

{"title":"Neuromedin U and BMI correlation in T1DM and T2DM vs healthy controls: A comparative study","authors":"Yasemin Çalışkan , Emre Sarandöl , Nizameddin Koca","doi":"10.1016/j.endien.2025.501631","DOIUrl":"10.1016/j.endien.2025.501631","url":null,"abstract":"<div><h3>Objective</h3><div>This study aimed to assess serum Neuromedin U (NmU) levels in patients with Type 1 (T1DM) and Type 2 diabetes mellitus (T2DM) vs healthy controls and evaluate the correlation between NmU and body mass index (BMI).</div></div><div><h3>Research design and methods</h3><div>We conducted a cross-sectional study with 134 participants: 45 with T1DM, 49 with T2DM, and 40 healthy controls. Serum NmU levels were measured using enzyme-linked immunosorbent assay (ELISA), and the correlation with BMI was assessed.</div></div><div><h3>Results</h3><div>NmU levels were not significantly different between diabetic patients and healthy controls. No significant correlation was observed between NmU and BMI in T1DM or T2DM groups. However, the healthy control group found a significant inverse correlation between NmU and BMI (rho=−0.373, <em>p</em>  <!-->0.05).</div></div><div><h3>Conclusions</h3><div>NmU may not be a direct biomarker for diabetes, but its significant correlation with BMI in healthy individuals suggests a potential role in metabolic regulation. This is the first study ever conducted to compare NmU levels across diabetic subtypes, offering novel insights into the role of in metabolic homeostasis.</div></div>","PeriodicalId":48650,"journal":{"name":"Endocrinologia Diabetes Y Nutricion","volume":"72 8","pages":"Article 501631"},"PeriodicalIF":1.8,"publicationDate":"2025-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145236393","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Active insulin time setting in MiniMed™ 780G: Impact on glucose control and patient perception MiniMed™780G的活性胰岛素时间设置：对血糖控制和患者感知的影响

IF 1.8 4区医学 Q4 ENDOCRINOLOGY & METABOLISM

Endocrinologia Diabetes Y Nutricion

Pub Date : 2025-10-01 Epub Date: 2025-10-07 DOI: 10.1016/j.endien.2025.501635

Fidel Jesús Enciso Izquierdo , María José Amaya García , Paula Gómez Turégano , María Luengo Andrada , Ana Alejandra Cordero Vaquero , José Antonio Lucas Gamero , Sergio Garrido Domínguez , Irene Álvarez Reyes

Introduction

The active insulin time (AIT) is an adjustable parameter of the MiniMed™ 780G (MM780G) system. We analyze glucose outcomes and patient perception at different AIT settings.

Method

We conducted a quasi-experimental study on type 1 diabetes mellitus patients treated with MM780G, seen consecutively in our center. AIT was set at 2, 3 and 4 h consecutively, during a 2-week period each. Glucose metrics, insulin delivery and a questionnaire about patient perception were evaluated. At the end, results were discussed with the patient and the most appropriate AIT was agreed upon.

Results

A total of 58 users were included, aged 18–65 years, 58.6% of whom were women. At baseline, 2-h AIT was set in 6.70% of the patients, >2-h AIT and ≤3-h AIT in 24.67%, >3-h AIT and ≤4-h AIT in 58.62%, and >4-h AIT in 10.34%. Under the 2-h AIT, TIR increased by 2.28% and 6.35% vs 3- and 4-h AIT, respectively. The auto-correction boluses percentage was 21.19% at 2-h AIT, 16.90% at 3-h AIT and 14.40% at 4-h AIT.

A total of 41.4% of the users considered that 3 h was the AIT that most met their needs and 43.1% felt safer and less vulnerable to hypoglycemia at this setting. After trying on different AIT durations, 2 h increased from 6.7% of participants to 62%.

Conclusion

At 2-h AIT, the system delivers more auto-correction insulin and improves TIR vs 3- and 4-h AIT. Patients feel safer and less susceptible to hypoglycemia at 3-h AIT, but 2 out of 3 would rather choose the 2-h AIT after knowing glycemic outcomes.

胰岛素活性时间（AIT）是MiniMed™780G （MM780G）系统的可调参数。我们分析了不同AIT设置下的血糖结果和患者感知。方法对1型糖尿病患者进行MM780G治疗的准实验研究，在本中心连续观察。AIT分别于2、3、4小时连续设置，每次2周。评估血糖指标、胰岛素输送和患者感知问卷。最后，与患者讨论结果并商定最合适的AIT。结果共纳入58例患者，年龄18 ~ 65岁，其中58.6%为女性。基线时，6.70%的患者有2小时AIT， 24.67%的患者有2小时AIT和≤3小时AIT， 58.62%的患者有3小时AIT和≤4小时AIT， 10.34%的患者有4小时AIT。经2 h处理后，TIR比3 h和4 h分别提高了2.28%和6.35%。2 h自动校正丸率为21.19%，3 h为16.90%，4 h为14.40%。共有41.4%的用户认为3小时是最能满足他们需求的AIT， 43.1%的用户认为在这个设置下更安全，更不容易发生低血糖。在尝试不同的AIT持续时间后，2小时的参与者从6.7%增加到62%。结论与3 h和4 h AIT相比，2 h AIT系统可提供更多的自动校正胰岛素，提高TIR。患者感觉3小时AIT更安全，更不易发生低血糖，但3人中有2人在了解血糖结果后更愿意选择2小时AIT。

{"title":"Active insulin time setting in MiniMed™ 780G: Impact on glucose control and patient perception","authors":"Fidel Jesús Enciso Izquierdo , María José Amaya García , Paula Gómez Turégano , María Luengo Andrada , Ana Alejandra Cordero Vaquero , José Antonio Lucas Gamero , Sergio Garrido Domínguez , Irene Álvarez Reyes","doi":"10.1016/j.endien.2025.501635","DOIUrl":"10.1016/j.endien.2025.501635","url":null,"abstract":"<div><h3>Introduction</h3><div>The active insulin time (AIT) is an adjustable parameter of the MiniMed™ 780G (MM780G) system. We analyze glucose outcomes and patient perception at different AIT settings.</div></div><div><h3>Method</h3><div>We conducted a quasi-experimental study on type 1 diabetes mellitus patients treated with MM780G, seen consecutively in our center. AIT was set at 2, 3 and 4h consecutively, during a 2-week period each. Glucose metrics, insulin delivery and a questionnaire about patient perception were evaluated. At the end, results were discussed with the patient and the most appropriate AIT was agreed upon.</div></div><div><h3>Results</h3><div>A total of 58 users were included, aged 18–65 years, 58.6% of whom were women. At baseline, 2-h AIT was set in 6.70% of the patients, >2-h AIT and ≤3-h AIT in 24.67%, >3-h AIT and ≤4-h AIT in 58.62%, and >4-h AIT in 10.34%. Under the 2-h AIT, TIR increased by 2.28% and 6.35% vs 3- and 4-h AIT, respectively. The auto-correction boluses percentage was 21.19% at 2-h AIT, 16.90% at 3-h AIT and 14.40% at 4-h AIT.</div><div>A total of 41.4% of the users considered that 3h was the AIT that most met their needs and 43.1% felt safer and less vulnerable to hypoglycemia at this setting. After trying on different AIT durations, 2h increased from 6.7% of participants to 62%.</div></div><div><h3>Conclusion</h3><div>At 2-h AIT, the system delivers more auto-correction insulin and improves TIR vs 3- and 4-h AIT. Patients feel safer and less susceptible to hypoglycemia at 3-h AIT, but 2 out of 3 would rather choose the 2-h AIT after knowing glycemic outcomes.</div></div>","PeriodicalId":48650,"journal":{"name":"Endocrinologia Diabetes Y Nutricion","volume":"72 8","pages":"Article 501635"},"PeriodicalIF":1.8,"publicationDate":"2025-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145236394","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Attention deficit hyperactivity disorder risk, mental health diagnoses and experience of discrimination in transgender adolescents and youth 跨性别青少年的注意缺陷多动障碍风险、心理健康诊断和歧视经历

IF 1.8 4区医学 Q4 ENDOCRINOLOGY & METABOLISM

Endocrinologia Diabetes Y Nutricion

Pub Date : 2025-10-01 Epub Date: 2025-09-12 DOI: 10.1016/j.endien.2025.501593

Carmen Martínez del Río , Isabel Cuellar-Flores , Diego López de Lara , Raúl Castañeda-Vozmediano , María Miguélez González , Alicia Gaitero Pérez , Olga Pérez Rodríguez , Adrián García Ron

Introduction

Recent studies suggest a higher prevalence of attention-deficit hyperactivity disorder (ADHD) in transgender individuals compared to the general population. However, no studies have been conducted in the Spanish population, and most focus on individuals with a prior ADHD diagnosis rather than screening for the disorder.

Materials and methods

This is a single-center, cross-sectional observational study assessing the risk of ADHD in transgender adolescents and young adults compared to cisgender individuals using the World Health Organization's (WHO) Adult ADHD Self-Report Scale (ASRS-V1.1). Additionally, previous mental health diagnoses and experiences of discrimination are analyzed in both groups.

Results

Transgender youth scored higher on the short-form scale, indicating a greater risk of ADHD, as well as on the hyperactivity/impulsivity subscale. A significant association was also found between experiences of discrimination and a prior diagnosis of depression.

Conclusions

The ASRS-V1.1 scale may be useful for ADHD screening in transgender individuals; however, further studies are needed to confirm these findings. Risk factors for neurodevelopmental and anxiety-depressive disorders may differ in the transgender population.

简介：最近的研究表明，与一般人群相比，变性人的注意力缺陷多动障碍（ADHD）患病率更高。然而，没有在西班牙人群中进行的研究，而且大多数研究都集中在先前诊断为多动症的个体上，而不是对这种疾病进行筛查。材料和方法：这是一项单中心、横断面观察性研究，使用世界卫生组织（WHO）成人ADHD自我报告量表（ASRS-V1.1）评估跨性别青少年和年轻人与顺性个体相比患ADHD的风险。此外，还分析了两组以前的心理健康诊断和歧视经历。结果：跨性别青年在短形式量表上得分更高，表明患多动症的风险更高，在多动/冲动子量表上也是如此。被歧视的经历和先前的抑郁症诊断之间也有显著的联系。结论：ASRS-V1.1量表可用于跨性别者ADHD筛查；然而，需要进一步的研究来证实这些发现。神经发育障碍和焦虑抑郁障碍的危险因素在跨性别人群中可能有所不同。

{"title":"Attention deficit hyperactivity disorder risk, mental health diagnoses and experience of discrimination in transgender adolescents and youth","authors":"Carmen Martínez del Río , Isabel Cuellar-Flores , Diego López de Lara , Raúl Castañeda-Vozmediano , María Miguélez González , Alicia Gaitero Pérez , Olga Pérez Rodríguez , Adrián García Ron","doi":"10.1016/j.endien.2025.501593","DOIUrl":"10.1016/j.endien.2025.501593","url":null,"abstract":"<div><h3>Introduction</h3><div>Recent studies suggest a higher prevalence of attention-deficit hyperactivity disorder (ADHD) in transgender individuals compared to the general population. However, no studies have been conducted in the Spanish population, and most focus on individuals with a prior ADHD diagnosis rather than screening for the disorder.</div></div><div><h3>Materials and methods</h3><div>This is a single-center, cross-sectional observational study assessing the risk of ADHD in transgender adolescents and young adults compared to cisgender individuals using the World Health Organization's (WHO) Adult ADHD Self-Report Scale (ASRS-V1.1). Additionally, previous mental health diagnoses and experiences of discrimination are analyzed in both groups.</div></div><div><h3>Results</h3><div>Transgender youth scored higher on the short-form scale, indicating a greater risk of ADHD, as well as on the hyperactivity/impulsivity subscale. A significant association was also found between experiences of discrimination and a prior diagnosis of depression.</div></div><div><h3>Conclusions</h3><div>The ASRS-V1.1 scale may be useful for ADHD screening in transgender individuals; however, further studies are needed to confirm these findings. Risk factors for neurodevelopmental and anxiety-depressive disorders may differ in the transgender population.</div></div>","PeriodicalId":48650,"journal":{"name":"Endocrinologia Diabetes Y Nutricion","volume":"72 8","pages":"Article 501593"},"PeriodicalIF":1.8,"publicationDate":"2025-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145058783","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Analysis of pituitary dysfunction in patients with hypothalamic-pituitary axis disorders not associated with pituitary adenomas 与垂体腺瘤无关的下丘脑-垂体轴疾病患者垂体功能障碍分析。

IF 1.8 4区医学 Q4 ENDOCRINOLOGY & METABOLISM

Endocrinologia Diabetes Y Nutricion

Pub Date : 2025-10-01 Epub Date: 2025-09-11 DOI: 10.1016/j.endien.2025.5015616

Fernando Guerrero-Pérez

引用次数: 0

Ectopic Cushing's syndrome in a patient with DIPNECH and metastatic lung carcinoid 异位库欣综合征伴DIPNECH和转移性肺类癌1例

IF 1.8 4区医学 Q4 ENDOCRINOLOGY & METABOLISM

Endocrinologia Diabetes Y Nutricion

Pub Date : 2025-10-01 Epub Date: 2025-10-07 DOI: 10.1016/j.endien.2025.501636

Sara Ribeiro , Telma Moreno , Maria Lume , Marisa C. Couto , Diana Baptista , Conceição Souto-Moura , Ana Varela , Sandra Belo , Paula Freitas , Davide Carvalho

Diffuse idiopathic pulmonary neuroendocrine cell hyperplasia (DIPNECH) is a rare precursor to lung carcinoids. We report a case of ACTH-dependent Cushing's syndrome in a 73-year-old female patient with metastatic lung carcinoid arising on a background of DIPNECH. She presented with lower limb oedema, hypokalaemia, hypertension, and de novo diabetes. Clinical suspicion for hypercortisolism was confirmed by abnormal cortisol tests. A thoracic CT scan showed multiple lung nodules suggestive of DIPNECH and biopsy of one of the nodules identified an ACTH-expressing carcinoid tumour. A PET-Ga-68-DOTATOC revealed pulmonary and multiple tumour lesions in the ganglia, bone and liver with overexpression of somatostatin receptors. A liver biopsy demonstrated involvement by a well-differentiated neuroendocrine neoplasia, consistent with metastasis. Hypercortisolism was managed with octreotide and metyrapone, but the patient succumbed to complications 14 months post-diagnosis. This case suggests DIPNECH's potential to progress to hyperfunctioning, metastatic carcinoids and highlights the necessity for vigilant long-term surveillance and early intervention.

弥漫性特发性肺神经内分泌细胞增生（DIPNECH）是一种罕见的肺类癌的前兆。我们报告一例acth依赖性库欣综合征在一个73岁的女性患者转移性肺类癌的背景下产生的DIPNECH。患者表现为下肢水肿、低钾血症、高血压和新发糖尿病。临床怀疑为高皮质醇症是由异常的皮质醇试验证实。胸部CT扫描显示多发肺结节提示DIPNECH，其中一个结节活检确定为表达acth的类癌。PET-Ga-68-DOTATOC显示肺和神经节、骨和肝脏多发肿瘤病变伴生长抑素受体过表达。肝活组织检查显示为分化良好的神经内分泌肿瘤，伴有转移。高皮质醇症用奥曲肽和metyrapone治疗，但患者在诊断后14个月死于并发症。本病例提示DIPNECH有可能发展为功能亢进、转移性类癌，并强调长期警惕监测和早期干预的必要性。

{"title":"Ectopic Cushing's syndrome in a patient with DIPNECH and metastatic lung carcinoid","authors":"Sara Ribeiro , Telma Moreno , Maria Lume , Marisa C. Couto , Diana Baptista , Conceição Souto-Moura , Ana Varela , Sandra Belo , Paula Freitas , Davide Carvalho","doi":"10.1016/j.endien.2025.501636","DOIUrl":"10.1016/j.endien.2025.501636","url":null,"abstract":"<div><div>Diffuse idiopathic pulmonary neuroendocrine cell hyperplasia (DIPNECH) is a rare precursor to lung carcinoids. We report a case of ACTH-dependent Cushing's syndrome in a 73-year-old female patient with metastatic lung carcinoid arising on a background of DIPNECH. She presented with lower limb oedema, hypokalaemia, hypertension, and de novo diabetes. Clinical suspicion for hypercortisolism was confirmed by abnormal cortisol tests. A thoracic CT scan showed multiple lung nodules suggestive of DIPNECH and biopsy of one of the nodules identified an ACTH-expressing carcinoid tumour. A PET-Ga-68-DOTATOC revealed pulmonary and multiple tumour lesions in the ganglia, bone and liver with overexpression of somatostatin receptors. A liver biopsy demonstrated involvement by a well-differentiated neuroendocrine neoplasia, consistent with metastasis. Hypercortisolism was managed with octreotide and metyrapone, but the patient succumbed to complications 14 months post-diagnosis. This case suggests DIPNECH's potential to progress to hyperfunctioning, metastatic carcinoids and highlights the necessity for vigilant long-term surveillance and early intervention.</div></div>","PeriodicalId":48650,"journal":{"name":"Endocrinologia Diabetes Y Nutricion","volume":"72 8","pages":"Article 501636"},"PeriodicalIF":1.8,"publicationDate":"2025-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145236395","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Executive summary of the document ‘Diabetes Day Hospital. Value proposition’ “糖尿病日医院”文件的执行摘要。价值主张”。

IF 1.8 4区医学 Q4 ENDOCRINOLOGY & METABOLISM

Endocrinologia Diabetes Y Nutricion

Pub Date : 2025-10-01 Epub Date: 2025-09-12 DOI: 10.1016/j.endien.2025.501601

Francisco Javier Escalada San Martín , Irene Bretón Lesmes , Fernando Gómez Peralta , Juan Francisco Merino Torres , Francisco Pomares Gómez , Ana Chico Ballesteros , José Miguel González-Clemente , Noemí González Pérez de Villar , Cristóbal Morales Portillo , Pedro José Pinés Corrales , Wifredo Ricart Engel , M. Teresa Benedito Pérez de Inestrosa , Carlos Miranda Fernández-Santos , Ezequiel Arranz , Guadalupe Fontán Vinagre , Juan Francisco Perán , Sedisa , María Asunción Martínez Brocca

引用次数: 0

首页上一页

下一页尾页

类型

全部化学•材料生命科学医学物理工程技术环境•农林材料科学地球科学法学管理学化学环境科学与生态学计算机科学教育学经济学农林科学人文科学生物学数学物理与天体物理心理学综合性期刊其他工业工程理学历史学农学文学信息工程

数据库

全部 ACS Publications Elsevier ieeexplore Springer The Royal Society of Chemistry Wiley

期刊

Endocrinologia Diabetes Y Nutricion

全部 Acc. Chem. Res. ACS Applied Bio Materials ACS Appl. Electron. Mater. ACS Appl. Energy Mater. ACS Appl. Mater. Interfaces ACS Appl. Nano Mater. ACS Appl. Polym. Mater. ACS BIOMATER-SCI ENG ACS Catal. ACS Cent. Sci. ACS Chem. Biol. ACS Chemical Health & Safety ACS Chem. Neurosci. ACS Comb. Sci. ACS Earth Space Chem. ACS Energy Lett. ACS Infect. Dis. ACS Macro Lett. ACS Mater. Lett. ACS Med. Chem. Lett. ACS Nano ACS Omega ACS Photonics ACS Sens. ACS Sustainable Chem. Eng. ACS Synth. Biol. Anal. Chem. BIOCHEMISTRY-US Bioconjugate Chem. BIOMACROMOLECULES Chem. Res. Toxicol. Chem. Rev. Chem. Mater. CRYST GROWTH DES ENERG FUEL Environ. Sci. Technol. Environ. Sci. Technol. Lett. Eur. J. Inorg. Chem. IND ENG CHEM RES Inorg. Chem. J. Agric. Food. Chem. J. Chem. Eng. Data J. Chem. Educ. J. Chem. Inf. Model. J. Chem. Theory Comput. J. Med. Chem. J. Nat. Prod. J PROTEOME RES J. Am. Chem. Soc. LANGMUIR MACROMOLECULES Mol. Pharmaceutics Nano Lett. Org. Lett. ORG PROCESS RES DEV ORGANOMETALLICS J. Org. Chem. J. Phys. Chem. J. Phys. Chem. A J. Phys. Chem. B J. Phys. Chem. C J. Phys. Chem. Lett. Analyst Anal. Methods Biomater. Sci. Catal. Sci. Technol. Chem. Commun. Chem. Soc. Rev. CHEM EDUC RES PRACT CRYSTENGCOMM Dalton Trans. Energy Environ. Sci. ENVIRON SCI-NANO ENVIRON SCI-PROC IMP ENVIRON SCI-WAT RES Faraday Discuss. Food Funct. Green Chem. Inorg. Chem. Front. Integr. Biol. J. Anal. At. Spectrom. J. Mater. Chem. A J. Mater. Chem. B J. Mater. Chem. C Lab Chip Mater. Chem. Front. Mater. Horiz. MEDCHEMCOMM Metallomics Mol. Biosyst. Mol. Syst. Des. Eng. Nanoscale Nanoscale Horiz. Nat. Prod. Rep. New J. Chem. Org. Biomol. Chem. Org. Chem. Front. PHOTOCH PHOTOBIO SCI PCCP Polym. Chem.

﹀